CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Alex Watterson, Gabriele Picco, Vivien Veninga, Youhani Samarakoon, Chiara Maria Cattaneo, Sara F. Vieira, Emre Karakoç, Shriram G. Bhosle, Thomas Battaglia, Sarah Consonni, Timotheus Y.F. Halim, Emile E. Voest, Mathew J. Garnett, Matthew A. Coelho
The paper identifies CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance through CRISPR screens and shows their potential as biomarkers for immunotherapy response.
Cell Reports Medicine · Jan 1, 2026Peer-reviewedCancer Biology